The CDC has endorsed the Advisory Committee on Immunization Practices’ (ACIP) recommendation of a new vaccine for COVID-19, the Novavax vaccine. Novavax’s COVID-19 vaccine is intended for adults 18 years and older.
The Novovax vaccine requires two doses, like the Pfizer vaccine. The two doses are given three to eight weeks apart. Novovax is not authorized for booster shots.
What’s different about Novavax?
Novavax is a protein-based vaccine, like the flu shot, HPV vaccine, and whooping cough vaccine. This means that it contains part of the COVID-19 virus’s spike protein. This protein subunit (that is, part) is harmless and does not cause COVID-19.
It is combined with an immune-boosting compound called an adjuvant. Together, the protein subunit and the adjuvant cause the body to have an immune response.
That way, when the body meets COVID-19 again, it’s ready to fight off the virus. It has learned from the vaccine how to fend off the COVID-19 virus, so people vaccinated. with Novavax are less likely to catch the disease and less likely to have a serious case of it if they do catch it.
Protein-based vaccines have been in use for more than 30 years, compared with the more familiar COVID-19 vaccines which use a newer technology.
The Novavax vaccine was 90% effective in clinical trials, which test new medications with volunteers. This testing was done before the Omicron and Delta variants developed. However, the vaccine is being used successfully in 40 countries, including Canada.
The Food and Drug Administration (FDA) approved Novavax on July 13, 2022. It has less specialized storage requirements than the Pfizer or Moderna vaccines. Makers hope that some of the 20% of U.S. adults who have still not been vaccinated will take advantage of this new opportunity. In Arkansas, only 55% of the population is fully vaccinated.
Call your doctor or a MANA clinic to schedule your vaccine.